Compare MKSI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | VTRS |
|---|---|---|
| Founded | 1961 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 17.2B |
| IPO Year | 1997 | 2019 |
| Metric | MKSI | VTRS |
|---|---|---|
| Price | $263.99 | $14.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $263.31 | $13.50 |
| AVG Volume (30 Days) | 921.9K | ★ 8.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | 0.37% | ★ 3.24% |
| EPS Growth | ★ 55.52 | N/A |
| EPS | ★ 4.37 | N/A |
| Revenue | $3,931,000,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $15.87 | $4.41 |
| Revenue Next Year | $10.87 | $1.96 |
| P/E Ratio | $61.52 | ★ N/A |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $70.51 | $8.19 |
| 52 Week High | $294.05 | $16.47 |
| Indicator | MKSI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 63.59 |
| Support Level | $208.96 | $12.90 |
| Resistance Level | $269.91 | $15.22 |
| Average True Range (ATR) | 11.91 | 0.41 |
| MACD | -1.29 | 0.11 |
| Stochastic Oscillator | 8.41 | 84.59 |
MKS Inc delivers foundational technology solutions for leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. The company provides instruments, components, subsystems, systems, process control solutions, and specialty chemicals technology that improve process performance and optimize productivity. Its solutions address challenges of miniaturization and complexity in device manufacturing, enabling increased power, speed, and feature enhancement. MKS Inc operates through three divisions: Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Materials Solutions Division (MSD). The company operates in the United States, which generates maximum revenue, as well as China and other countries.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.